Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...
2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump—which is tubeless, fully wearable and can be completely controlled ...
The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
As a child with Type 1 diabetes, Arden Benner of Robbinsville, New Jersey, has gotten used to needle sticks and injections. Scott Benner, her father, says, "21 injections every 3 days, plus her finger ...
Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results